RU2014102764A - Способ получения хиральных ингибиторов дипептидилпептидазы iv - Google Patents
Способ получения хиральных ингибиторов дипептидилпептидазы iv Download PDFInfo
- Publication number
- RU2014102764A RU2014102764A RU2014102764/04A RU2014102764A RU2014102764A RU 2014102764 A RU2014102764 A RU 2014102764A RU 2014102764/04 A RU2014102764/04 A RU 2014102764/04A RU 2014102764 A RU2014102764 A RU 2014102764A RU 2014102764 A RU2014102764 A RU 2014102764A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- formula iii
- base
- solvent
- Prior art date
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 31
- 238000000034 method Methods 0.000 claims abstract 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract 10
- 239000002904 solvent Substances 0.000 claims abstract 10
- 230000006103 sulfonylation Effects 0.000 claims abstract 8
- 238000005694 sulfonylation reaction Methods 0.000 claims abstract 8
- 238000006317 isomerization reaction Methods 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 7
- 125000006239 protecting group Chemical group 0.000 claims abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical group C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003960 organic solvent Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical group CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- -1 2,5-difluorophenyl Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- ZDUOFTTYDZYWNT-NJXYFUOMSA-N C[C@H](C(C1)NP)OCC1=O Chemical compound C[C@H](C(C1)NP)OCC1=O ZDUOFTTYDZYWNT-NJXYFUOMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502497P | 2011-06-29 | 2011-06-29 | |
| US61/502,497 | 2011-06-29 | ||
| PCT/US2012/043924 WO2013003250A1 (en) | 2011-06-29 | 2012-06-25 | Process for preparing chiral dipeptidyl peptidase-iv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014102764A true RU2014102764A (ru) | 2015-08-10 |
Family
ID=47424494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102764/04A RU2014102764A (ru) | 2011-06-29 | 2012-06-25 | Способ получения хиральных ингибиторов дипептидилпептидазы iv |
| RU2014102773/04A RU2598072C2 (ru) | 2011-06-29 | 2012-06-25 | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102773/04A RU2598072C2 (ru) | 2011-06-29 | 2012-06-25 | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9187488B2 (enExample) |
| EP (2) | EP2726075A4 (enExample) |
| JP (4) | JP2014518266A (enExample) |
| KR (2) | KR20140034861A (enExample) |
| CN (3) | CN103702562A (enExample) |
| AR (1) | AR089554A1 (enExample) |
| AU (2) | AU2012275638A1 (enExample) |
| CA (2) | CA2838738A1 (enExample) |
| MX (2) | MX341299B (enExample) |
| RU (2) | RU2014102764A (enExample) |
| TW (1) | TWI574965B (enExample) |
| WO (2) | WO2013003249A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012275638A1 (en) | 2011-06-29 | 2013-11-14 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitors |
| US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP2874626A4 (en) | 2012-07-23 | 2016-03-23 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| US9937153B2 (en) | 2013-08-30 | 2018-04-10 | Merck Sharp & Dohme Ltd. | Oral pharmaceutical formulation of omarigliptin |
| EP2997008B1 (en) * | 2014-03-20 | 2016-06-29 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of key intermediates of omarigliptin |
| CN105037367A (zh) * | 2014-04-18 | 2015-11-11 | 四川海思科制药有限公司 | 氨基六元环类衍生物及其在医药上的应用 |
| CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
| JP6574474B2 (ja) * | 2014-07-21 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法 |
| WO2016015596A1 (en) * | 2014-07-29 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Process for preparing 2, 3-disubstituted-5-oxopyran compound |
| CN106316888B (zh) * | 2015-06-29 | 2018-05-18 | 深圳翰宇药业股份有限公司 | 一种手性氨基吡喃酮类化合物的合成方法 |
| WO2017032705A1 (en) | 2015-08-25 | 2017-03-02 | Sandoz Ag | Crystalline form of omarigliptin |
| CN105130995B (zh) * | 2015-09-09 | 2017-08-11 | 杭州成邦医药科技有限公司 | 吡咯酮类化合物及其制备方法和应用 |
| WO2017081590A1 (en) * | 2015-11-09 | 2017-05-18 | Sun Pharmaceutical Industries Limited | Process for the preparation of omarigliptin |
| CN105348286B (zh) * | 2015-11-25 | 2018-12-18 | 中山奕安泰医药科技有限公司 | 一种2-甲基磺酰基-2,4,5,6-四氢吡咯[3，4-c]吡唑苯磺酸盐的制备方法 |
| WO2017093209A1 (en) | 2015-12-03 | 2017-06-08 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for preparing aminotetrahydropyrans |
| CN105399744B (zh) * | 2015-12-17 | 2017-07-18 | 黄燕鸽 | 一种奥格列汀的合成方法 |
| EP3181565A1 (en) | 2015-12-18 | 2017-06-21 | Sandoz Ag | Crystalline omarigliptin salts |
| CN107849051B (zh) * | 2015-12-25 | 2020-11-13 | 四川海思科制药有限公司 | 取代的氨基吡喃衍生物的晶型 |
| CN106928228B (zh) * | 2015-12-29 | 2019-08-30 | 杭州普晒医药科技有限公司 | 奥格列汀盐及其晶型、它们的制备方法和药物组合物 |
| CN107652291B (zh) * | 2016-07-26 | 2020-07-14 | 中国科学院上海药物研究所 | 一种制备手性四氢吡喃衍生物的方法 |
| US10822319B2 (en) * | 2016-08-12 | 2020-11-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of DPP-IV long-acting inhibitor and salt |
| CN107793389B (zh) * | 2016-09-05 | 2021-06-29 | 中国科学院上海药物研究所 | 手性四氢吡喃衍生物及其制备与用途 |
| KR102599958B1 (ko) * | 2016-09-28 | 2023-11-09 | (주)아모레퍼시픽 | (r)-n-[4-(1-아미노-에틸)-2,6-다이플루오로-페닐]-메테인설폰아마이드의 제조방법 |
| CN106674227B (zh) * | 2016-12-06 | 2019-03-19 | 上海博志研新药物技术有限公司 | 一种奥格列汀及其中间体的制备方法 |
| EP3335701A1 (en) | 2016-12-16 | 2018-06-20 | Hexal AG | Pharmaceutical composition comprising omarigliptin |
| EP3335703A1 (en) | 2016-12-16 | 2018-06-20 | Hexal AG | Pharmaceutical composition comprising omarigliptin |
| EP3335704A1 (en) | 2016-12-16 | 2018-06-20 | Hexal AG | Pharmaceutical composition comprising omarigliptin |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| CN109651203B (zh) * | 2019-01-22 | 2021-10-15 | 河南医学高等专科学校 | Dp-iv抑制剂奥格列汀中间体的制备方法 |
| CN110453177A (zh) * | 2019-08-06 | 2019-11-15 | 太仓碧奇新材料研发有限公司 | 一种柔性有机整流器的制备方法 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| CN111793071B (zh) * | 2020-07-06 | 2021-06-04 | 四川凯科医药科技有限公司 | 奥格列汀的合成工艺 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041442A (en) | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
| NZ337164A (en) * | 1997-03-21 | 2001-05-25 | Du Pont Pharm Co | Method of preparing 4-arylamino-1-alkyl-[1,2,3]-triazolo][4,5-c]pyridine derivatives |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| CN1243707C (zh) | 2000-09-14 | 2006-03-01 | 国家海洋局第一海洋研究所 | 共轭亚油酸的制造方法 |
| ATE395912T1 (de) | 2001-03-27 | 2008-06-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| CA2450475A1 (en) | 2001-06-20 | 2003-01-03 | Linda Brockunier | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP2004535433A (ja) | 2001-06-20 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用のジペプチジルペプチダーゼ阻害薬 |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| CN1212303C (zh) | 2001-12-31 | 2005-07-27 | 中国科学院新疆理化技术研究所 | 使用混合溶剂合成共轭亚油酸的方法 |
| US7307164B2 (en) | 2002-03-25 | 2007-12-11 | Merck & Co., Inc. | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DE60330485D1 (de) | 2002-07-15 | 2010-01-21 | Merck & Co Inc | Zur behandlung von diabetes |
| EP1554280B1 (en) | 2002-10-07 | 2007-08-15 | Merck & Co., Inc. | Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
| PL216527B1 (pl) | 2002-10-18 | 2014-04-30 | Merck & Co Inc | Związki ß-aminoheterocykliczne i kompozycja farmaceutyczna |
| EP1562925B1 (en) | 2002-11-07 | 2007-01-03 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CA2508487A1 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1583534A4 (en) | 2002-12-20 | 2007-08-29 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| CA2512546A1 (en) | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CA2513684A1 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| ATE441994T1 (de) * | 2003-04-03 | 2009-09-15 | Nokia Corp | Verwaltung von kontext-bezogener information mit einer mobilstation |
| CN1787823A (zh) | 2003-05-14 | 2006-06-14 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的3－氨基－4－苯基丁酸衍生物 |
| CN1798556A (zh) | 2003-06-06 | 2006-07-05 | 麦克公司 | 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚 |
| WO2004112701A2 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| CA2533893A1 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP2007510651A (ja) | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体 |
| CN1950349A (zh) | 2004-05-04 | 2007-04-18 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物 |
| JP2007538079A (ja) | 2004-05-18 | 2007-12-27 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのシクロヘキシルアラニン誘導体 |
| US7482336B2 (en) | 2004-06-21 | 2009-01-27 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2006023750A2 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US7884104B2 (en) | 2004-10-01 | 2011-02-08 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2006065826A2 (en) | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Process to chiral beta amino acid derivatives by asymmetric hydrogenation |
| EP1841770B1 (en) | 2005-01-19 | 2009-11-11 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2006104997A2 (en) | 2005-03-29 | 2006-10-05 | Merck & Co., Inc. | Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor |
| AU2006242219A1 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity |
| WO2006127530A2 (en) | 2005-05-25 | 2006-11-30 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US20090221592A1 (en) | 2005-07-25 | 2009-09-03 | Ellison Martha E | Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
| CA2619111C (en) | 2005-08-26 | 2013-04-09 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| EP1962601B1 (en) | 2005-12-14 | 2014-10-15 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| US8414921B2 (en) | 2005-12-16 | 2013-04-09 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| US7750034B2 (en) | 2006-01-25 | 2010-07-06 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US7910596B2 (en) | 2006-02-15 | 2011-03-22 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| TW200806669A (en) * | 2006-03-28 | 2008-02-01 | Merck & Co Inc | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| CA2652367A1 (en) | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CA2668662A1 (en) | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2009025784A1 (en) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| EP2228366B1 (de) | 2009-03-12 | 2011-12-28 | Archimica GmbH | Verfahren zur Herstellung von 2-Amino-4-(halogenalkyl)pyridin-Derivaten durch Cyclisierung geeigneter Nitril-Vorstufen mit Stickstoff-Verbindungen |
| KR20120092096A (ko) * | 2009-09-02 | 2012-08-20 | 머크 샤프 앤드 돔 코포레이션 | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ｉｖ 억제제로서의 아미노테트라히드로피란 |
| US8716482B2 (en) | 2009-09-25 | 2014-05-06 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
| US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2012078448A1 (en) | 2010-12-06 | 2012-06-14 | Schering Corporation | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| WO2012118945A2 (en) | 2011-03-03 | 2012-09-07 | Merck Sharp & Dohme Corp. | Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| AU2012275638A1 (en) | 2011-06-29 | 2013-11-14 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitors |
| US9051329B2 (en) | 2011-07-05 | 2015-06-09 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
| JP6480788B2 (ja) * | 2015-04-07 | 2019-03-13 | 株式会社マキタ | 打撃工具 |
-
2012
- 2012-06-25 AU AU2012275638A patent/AU2012275638A1/en not_active Abandoned
- 2012-06-25 WO PCT/US2012/043922 patent/WO2013003249A1/en not_active Ceased
- 2012-06-25 WO PCT/US2012/043924 patent/WO2013003250A1/en not_active Ceased
- 2012-06-25 AU AU2012275637A patent/AU2012275637B2/en not_active Ceased
- 2012-06-25 KR KR1020137034362A patent/KR20140034861A/ko not_active Withdrawn
- 2012-06-25 EP EP12803996.3A patent/EP2726075A4/en not_active Withdrawn
- 2012-06-25 KR KR1020137034363A patent/KR20140034862A/ko not_active Withdrawn
- 2012-06-25 US US14/119,063 patent/US9187488B2/en active Active
- 2012-06-25 RU RU2014102764/04A patent/RU2014102764A/ru not_active Application Discontinuation
- 2012-06-25 CN CN201280032105.4A patent/CN103702562A/zh active Pending
- 2012-06-25 RU RU2014102773/04A patent/RU2598072C2/ru not_active IP Right Cessation
- 2012-06-25 TW TW101122687A patent/TWI574965B/zh not_active IP Right Cessation
- 2012-06-25 CA CA2838738A patent/CA2838738A1/en not_active Abandoned
- 2012-06-25 CN CN201280032077.6A patent/CN103987388A/zh active Pending
- 2012-06-25 CN CN201610882581.5A patent/CN106946886A/zh active Pending
- 2012-06-25 MX MX2013014891A patent/MX341299B/es active IP Right Grant
- 2012-06-25 MX MX2013014892A patent/MX2013014892A/es not_active Application Discontinuation
- 2012-06-25 US US14/118,998 patent/US8895603B2/en active Active
- 2012-06-25 JP JP2014518879A patent/JP2014518266A/ja active Pending
- 2012-06-25 EP EP12804259.5A patent/EP2725905A4/en not_active Withdrawn
- 2012-06-25 CA CA2838748A patent/CA2838748A1/en not_active Abandoned
- 2012-06-25 JP JP2014518880A patent/JP5873554B2/ja active Active
- 2012-06-28 AR ARP120102322A patent/AR089554A1/es unknown
-
2014
- 2014-10-06 US US14/507,001 patent/US9181262B2/en active Active
-
2015
- 2015-10-02 US US14/873,641 patent/US9527855B2/en active Active
-
2016
- 2016-10-07 JP JP2016198829A patent/JP2017039752A/ja active Pending
-
2018
- 2018-03-23 JP JP2018055962A patent/JP2018115191A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014102764A (ru) | Способ получения хиральных ингибиторов дипептидилпептидазы iv | |
| EA201490831A1 (ru) | Способ получения хинолиновых производных | |
| JP2018522012A5 (enExample) | ||
| RU2014137470A (ru) | Способы и соединения, которые можно использовать для синтеза антагонистов рецепторов орексина-2 | |
| JP2008523069A5 (enExample) | ||
| CA2587528A1 (en) | Method for preparing n-phenylpyrazole-1-carboxamides | |
| JP2007531794A5 (enExample) | ||
| JP2015509939A5 (enExample) | ||
| RU2010125902A (ru) | Способ получения замещенных гетероциклом производных пиридина | |
| UA109883C2 (uk) | Спосіб отримання сполук для застосування як інгібіторів sglt2 | |
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| RU2014143116A (ru) | Способы синтеза этилфумаратов и их применение в качестве промежуточных соединений | |
| RU2009140324A (ru) | Получение фталоцианинов кремния и германия и родственных субстанций | |
| RU2009105669A (ru) | Способ получения 3-замещенных 2-амино-5-галогенбензамидов | |
| RU2011133749A (ru) | Способ получения и выделения 2-ациламино-3-дифенилпропионовой кислоты | |
| JP2017523124A5 (enExample) | ||
| RU2013147998A (ru) | Способ получения дронедарона посредством n-бутилирования | |
| RU2009138136A (ru) | Новый способ получения соединения 2-гидрокси-3-[5-(морфолин-4-илметил)пиридин-2-ил]1н-индол-5-карбонитрила 701 | |
| JP2020523378A5 (enExample) | ||
| MX2010003148A (es) | Procedimiento para la preparacion de diamidas de acido sulfonico. | |
| RU2017144050A (ru) | Способ синтеза производных рапамицина | |
| RU2012128887A (ru) | Способ получения гидрохлорида моксифлоксацина и его промежуточных продуктов | |
| HRP20080510T3 (hr) | Postupak za priređivanje optički aktivnih derivata 2-(2-piridilmetilsulfinil)-benzimidazola putem inkluzijskog kompleksa s 1,1'-binaftalen-2,2' diolom | |
| RU2014129937A (ru) | Способы и промежуточные соединения для получения фармацевтических агентов | |
| RU2010115566A (ru) | Ускоренное восстановление амидов и сложных эфиров аминоборанами и добавками |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161007 |